Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02345772 | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy(Neohttp) | terminated | Phase 1 / Phase 2 | 4 | Western Regional Medical CenterOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01484041 | Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 12 | Georgetown UniversityOTHER | 1 | Feb 9, 2018 | clinicaltrials |
| NCT00095862 | Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers | terminated | Phase 1 / Phase 2 | 24 | Wiseman Research Initiatives LLCINDUSTRY | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00864175 | Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 68 | Incyte CorporationINDUSTRY | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01929941 | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies | terminated | Phase 1 | 5 | Incyte CorporationINDUSTRY | 1 | Jan 17, 2018 | clinicaltrials |
| NCT01815346 | Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 12, 2018 | clinicaltrials |
| NCT00470548 | Abraxane and Alimta in Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 49 | University of California, DavisOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01372618 | Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor | terminated | Phase 1 / Phase 2 | 9 | NYU Langone HealthOTHER | 1 | Dec 27, 2017 | clinicaltrials |
| NCT00005993 | Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer | terminated | Phase 1 | — | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT01649258 | Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy | terminated | Phase 1 | 29 | University of Southern CaliforniaOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT00622401 | Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12 | terminated | Phase 1 / Phase 2 | 8 | Beth Israel Deaconess Medical CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02250118 | Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer(BEVAP) | terminated | Phase 1 | 1 | Institut CurieOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT01512199 | Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | terminated | Phase 1 / Phase 2 | 29 | Daiichi SankyoINDUSTRY | 2 | Oct 18, 2017 | clinicaltrials |
| NCT01939418 | Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 23 | National Cancer Center, KoreaOTHER_GOV | 1 | Oct 3, 2017 | clinicaltrials |
| NCT02074878 | CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer(CRIZENT) | terminated | Phase 1 | 3 | Mothaffar RimawiOTHER | 1 | Aug 9, 2017 | clinicaltrials |
| NCT00041470 | Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial | terminated | Phase 1 / Phase 2 | 38 | University of WashingtonOTHER | 1 | Jul 17, 2017 | clinicaltrials |
| NCT01918306 | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 11 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT00932035 | Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer | terminated | Phase 1 / Phase 2 | 39 | City of Hope Medical CenterOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT00904423 | Ph I/II of Vitamin D on Bone Mineral Density & Markers of Bone Resorption | terminated | Phase 1 / Phase 2 | 8 | Mark PegramOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT00301106 | Biological Therapy in Treating Women With Breast Cancer That Has Spread to the Liver | terminated | Phase 1 | 2 | Max SungOTHER | 1 | Feb 2, 2017 | clinicaltrials |
| NCT01132664 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | terminated | Phase 1 / Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 6 | Aug 17, 2016 | clinicaltrials |
| NCT01805908 | Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)(PETRA) | terminated | Phase 1 | 3 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00567879 | A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | terminated | Phase 1 / Phase 2 | 56 | Novartis PharmaceuticalsINDUSTRY | 6 | May 9, 2016 | clinicaltrials |
| NCT00346229 | Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | terminated | Phase 1 | 29 | Duke UniversityOTHER | 1 | Mar 22, 2016 | clinicaltrials |
| NCT02131506 | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer(CAELYX) | terminated | Phase 1 | 11 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Feb 2, 2016 | clinicaltrials |
| NCT00216047 | PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 7 | Hoosier Cancer Research NetworkOTHER | 1 | Dec 9, 2015 | clinicaltrials |
| NCT01056757 | Treatment With Ribavirin for Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 4 | Jewish General HospitalOTHER | 1 | Nov 4, 2015 | clinicaltrials |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 79 | Otsuka Novel Products GmbHINDUSTRY | 1 | Oct 20, 2015 | clinicaltrials |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer | terminated | Phase 1 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01281163 | Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer | terminated | Phase 1 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2015 | clinicaltrials |
| NCT01334099 | Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients | terminated | Phase 1 | 6 | University Health Network, TorontoOTHER | 1 | Jun 22, 2015 | clinicaltrials |
| NCT01149356 | RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | May 25, 2015 | clinicaltrials |
| NCT01071564 | RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery | terminated | Phase 1 | 13 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00450879 | Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery | terminated | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Mar 25, 2015 | clinicaltrials |
| NCT02024074 | Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients | terminated | Phase 1 | 1 | Emory UniversityOTHER | 1 | Feb 6, 2015 | clinicaltrials |
| NCT00539968 | A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED) | terminated | Phase 1 / Phase 2 | 5 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 5, 2015 | clinicaltrials |
| NCT00903006 | Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer | terminated | Phase 1 / Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 2, 2015 | clinicaltrials |
| NCT01194908 | Re-expression of ER in Triple Negative Breast Cancers | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00511576 | Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors | terminated | Phase 1 | 54 | Mirati Therapeutics Inc.INDUSTRY | 1 | Jan 8, 2015 | clinicaltrials |
| NCT01238029 | Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer(CELAVIE) | terminated | Phase 1 | 12 | Sponsor GmbHOTHER | 1 | Nov 21, 2014 | clinicaltrials |
| NCT01333137 | A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin | terminated | Phase 1 | 11 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | terminated | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT01131364 | Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | terminated | Phase 1 / Phase 2 | 29 | Philogen S.p.A.INDUSTRY | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00071942 | Vaccine Therapy in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2013 | clinicaltrials |
| NCT00003432 | Immunotherapy in Treating Patients With Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 4 | Duke UniversityOTHER | 1 | Nov 6, 2013 | clinicaltrials |
| NCT01060514 | Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer | terminated | Phase 1 | 8 | Northwestern UniversityOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00726180 | Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer | terminated | Phase 1 / Phase 2 | 1 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 15, 2013 | clinicaltrials |
| NCT01208441 | RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer | terminated | Phase 1 | 28 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01705340 | Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery | terminated | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Feb 20, 2018source: clinicaltrials